“`html

The Ozempic Revolution: Beyond Weight Loss

A needle, a prick and hundreds of promises. Considering the latest scientific research, it may seem that ‘Ozempic’-type medications already work for “almost everything.” What started as a treatment for type 2 diabetes has become the most talked-about medical phenomenon of the decade: an injection that promises to control blood sugar, protect the heart, help quit smoking, reduce the risk of several types of cancer and – of course, what has unleashed its global fame – cause unprecedented weight loss.

Medicine is experiencing a revolution after having found a biological target that acts on a key hormone: the glucagon-like peptide 1 (GLP-1) present in a large part of the body and involved in functions as basic as appetite, digestion and glucose regulation. Its discovery has changed the rules of the game, not onyl for endocrinologists, but also for cardiologists, nephrologists and psychiatrists, who are beginning to see a new therapeutic horizon in these compounds.

But amid the enthusiasm and expectation in headlines and social networks, questions are also growing. three new Cochrane reviews, commissioned by the World Health Organization (WHO), confirm that drugs such as ozempic, Wegovy or Mounjaro cause clinically significant weight loss… even though the researchers issue a warning: Most of the studies come from research funded by the pharmaceutical industry itself.

They affirm that there is a lack of greater transparency in the results, that long-term safety data are limited and that the side effects are not minor. In other words: its “miracle for almost everything” effect could have more than a few nuances. “It’s an exciting time after decades of unsuccessful attempts to find effective treatments for obesity,” summarizes Juan Franco, co-principal investigator at Heinrich Heine University Düsseldorf, “but we still don’t have all the answers.”

A Scientific Revolution Centered on GLP-1

The GLP-1 receptor is found not only in the pancreas, were it stimulates insulin secretion, but also in the brain, heart, kidneys and blood vessels. This widespread presence explains why GLP-1 agonists – the class of drugs to which Ozempic,Wegovy and Mounjaro belong – have such diverse effects.

How GLP-1 Agonists Work

• Blood Sugar Control: They enhance insulin release in response to glucose, lowering blood sugar levels.
• Weight Loss: They slow gastric emptying, increase feelings of fullness, and reduce appetite.
• Cardiovascular Benefits: Studies suggest they can reduce the risk of heart attack and stroke.
• Potential Cancer Prevention: Emerging research indicates a possible link between GLP-1 agonists and a reduced risk of certain cancers, though more research is needed.
• Smoking Cessation: Some studies show they can help reduce cravings and withdrawal symptoms.

The concerns and Caveats

Despite the promising results, experts caution against viewing these drugs as a panacea. The WHO-commissioned Cochrane reviews highlight several critical issues:

“The vast majority of evidence comes from studies funded by pharmaceutical companies,raising concerns about potential bias. Long-term safety data are lacking, and the reported side effects – nausea, vomiting, diarrhea, constipation – can be significant and impact quality of life.”

Side Effects to Consider

• Nausea
• vomiting
• diarrhea
• Constipation
• Pancreatitis (rare but serious)
• Gallbladder problems